WO2024252368A3 - Methods and compositions for treating ulcerative colitis - Google Patents

Methods and compositions for treating ulcerative colitis Download PDF

Info

Publication number
WO2024252368A3
WO2024252368A3 PCT/IB2024/055621 IB2024055621W WO2024252368A3 WO 2024252368 A3 WO2024252368 A3 WO 2024252368A3 IB 2024055621 W IB2024055621 W IB 2024055621W WO 2024252368 A3 WO2024252368 A3 WO 2024252368A3
Authority
WO
WIPO (PCT)
Prior art keywords
ulcerative colitis
methods
compositions
treating ulcerative
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2024/055621
Other languages
French (fr)
Other versions
WO2024252368A2 (en
Inventor
Maria PARASKEVOPOULOU
Eleonora A.M. FESTEN
Emilia BIGAEVA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of WO2024252368A2 publication Critical patent/WO2024252368A2/en
Publication of WO2024252368A3 publication Critical patent/WO2024252368A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention provides methods and compositions related to methods for determining whether a human subject having ulcerative colitis will respond to treatment with a humanized antibody having binding specificity for human α4β7 integrin for treating ulcerative colitis. The invention provides response markers that can be used to identify responders of ulcerative colitis.
PCT/IB2024/055621 2023-06-09 2024-06-08 Methods and compositions for treating ulcerative colitis Ceased WO2024252368A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202363507369P 2023-06-09 2023-06-09
US63/507,369 2023-06-09
US202363590182P 2023-10-13 2023-10-13
US63/590,182 2023-10-13

Publications (2)

Publication Number Publication Date
WO2024252368A2 WO2024252368A2 (en) 2024-12-12
WO2024252368A3 true WO2024252368A3 (en) 2025-02-13

Family

ID=91664853

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2024/055621 Ceased WO2024252368A2 (en) 2023-06-09 2024-06-08 Methods and compositions for treating ulcerative colitis

Country Status (1)

Country Link
WO (1) WO2024252368A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121889424A (en) 2023-08-14 2026-04-17 派拉冈医疗公司 α4β7 integrin-binding protein and its usage
CN121754644A (en) * 2026-03-04 2026-03-31 苏州大学 Application of CXCL14 recombinant protein in preparation of medicine for preventing or treating radiation enteritis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220364171A1 (en) * 2018-11-23 2022-11-17 Katholieke Universiteit Leuven Predicting a treatment response in inflammatory bowel disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (en) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド Modifications of or for denatured antibodies
WO1989007142A1 (en) 1988-02-05 1989-08-10 Morrison Sherie L Domain-modified constant region antibodies
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
WO1996024673A1 (en) 1995-02-10 1996-08-15 Leukosite, Inc. Mucosal vascular addressins and uses thereof
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US20010046496A1 (en) 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
WO2006026759A2 (en) 2004-09-03 2006-03-09 Genentech, Inc. Humanized anti-beta7 antagonists and uses therefor
EP1948691A1 (en) 2005-11-17 2008-07-30 Millennium Pharmaceuticals, Inc. HUMANIZED IMMUNOGLOBULIN REACTIVE WITH a4ß7INTEGRIN
CN103382222B (en) 2009-03-20 2016-12-28 安姆根有限公司 α-4-β-7 heterodimer specific antagonist antibody
MX367097B (en) 2011-05-02 2019-08-05 Millennium Pharm Inc FORMULATION FOR ANTI-a4ß7 ANTIBODY.
UA116189C2 (en) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. COMPOSITION OF ANTI-α4β7 ANTIBODY

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220364171A1 (en) * 2018-11-23 2022-11-17 Katholieke Universiteit Leuven Predicting a treatment response in inflammatory bowel disease

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ARIJS INGRID ET AL: "Effect of vedolizumab (anti-[alpha]4[beta]7-integrin) therapy on histological healing and mucosal gene expression in patients with UC", GUT MICROBIOTA, vol. 67, no. 1, 7 October 2016 (2016-10-07), UK, pages 43 - 52, XP093234548, ISSN: 0017-5749, Retrieved from the Internet <URL:https://gut.bmj.com/content/gutjnl/67/1/43.full.pdf> DOI: 10.1136/gutjnl-2016-312293 *
DE GALAN CARA ET AL: "Role of integrin expression in the prediction of response to?vedolizumab: A prospective real-life multicentre cohort?study", CLINICAL AND TRANSLATIONAL MEDICINE, vol. 12, no. 4, 1 April 2022 (2022-04-01), SE, XP093203941, ISSN: 2001-1326, Retrieved from the Internet <URL:https://onlinelibrary.wiley.com/doi/full-xml/10.1002/ctm2.769> DOI: 10.1002/ctm2.769 *
FESTEN ELEONORA ET AL: "High-dimensional single-cell analysis identifies cellular signatures associated with response to vedolizumab therapy in ulcerative colitis", RESEARCH SQUARE, 12 September 2023 (2023-09-12), XP093204249, Retrieved from the Internet <URL:https://www.researchgate.net/publication/374408119_High-dimensional_single-cell_analysis_identifies_cellular_signatures_associated_with_response_to_vedolizumab_therapy_in_ulcerative_colitis> DOI: 10.21203/rs.3.rs-3348629/v1 *
GAZOULI MARIA ET AL: "Response to Anti-[alpha]4[beta]7 Blockade in Patients With Ulcerative Colitis Is Associated With Distinct Mucosal Gene Expression Profiles at Baseline", HHS PUBLIC ACCESS AUTHOR MANUSCRIPT, vol. 28, no. 1, 27 May 2021 (2021-05-27), US, pages 87 - 95, XP093205166, ISSN: 1078-0998, Retrieved from the Internet <URL:https://academic.oup.com/ibdjournal/article-pdf/28/1/87/45808475/izab117.pdf> DOI: 10.1093/ibd/izab117 *
HSU PAUL ET AL: "Responsiveness to Vedolizumab Therapy in Ulcerative Colitis is Associated With Alterations in Immune Cell-Cell Communications", HHS PUBLIC ACCESS AUTHOR MANUSCRIPT, vol. 29, no. 10, 26 May 2023 (2023-05-26), US, pages 1602 - 1612, XP093204254, ISSN: 1078-0998, Retrieved from the Internet <URL:https://academic.oup.com/ibdjournal/article-pdf/29/10/1602/51840044/izad084.pdf> DOI: 10.1093/ibd/izad084 *
KARMI N. ET AL: "Single-cell analysis of gut mucosal- and peripheral blood cells in ulcerative colitis patients undergoing vedolizumab treatment", JOURNAL OF CROHN'S AND COLITIS, vol. 16, no. Suppl 1, 1 January 2022 (2022-01-01), pages i153 - i154, XP093204251, Retrieved from the Internet <URL:https://academic.oup.com/ecco-jcc/article/16/Supplement_1/i153/6512476> *
PIBIRI P ET AL: "Abstract citation ID: jjac190.0005 OP05 High-dimensional single-cell analysis identifies cellular signatures associated with response to vedolizumab therapy in ulcerative colitis", 30 January 2023 (2023-01-30), XP093234538, Retrieved from the Internet <URL:https://watermark.silverchair.com/jjac190.0005.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAA5IwggOOBgkqhkiG9w0BBwagggN_MIIDewIBADCCA3QGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMscteDltrd0HBTk-PAgEQgIIDRQH-caDIvE1HbcyUGsA1c2DzgZSrM3Mpxv7MnNUuc8B7R1Oay0MEx_wuQp90JL5sI25Aweg75yzUKE92emZJF_g> *
VERSTOCKT BRAM ET AL: "Expression Levels of 4 Genes in Colon Tissue Might Be Used to Predict Which Patients Will Enter Endoscopic Remission After Vedolizumab Therapy for Inflammatory Bowel Diseases", CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 18, no. 5, 22 August 2019 (2019-08-22), pages 1142, XP086134038, ISSN: 1542-3565, [retrieved on 20190822], DOI: 10.1016/J.CGH.2019.08.030 *
WEI KEVIN ET AL: "Fibroblast pathology in inflammatory diseases", JOURNAL OF CLINICAL INVESTIGATION, vol. 131, no. 20, 15 October 2021 (2021-10-15), XP093044940, Retrieved from the Internet <URL:https://dm5migu4zj3pb.cloudfront.net/manuscripts/149000/149538/cache/149538.1-20211006180935-covered-e0fd13ba177f913fd3156f593ead4cfd.pdf> DOI: 10.1172/JCI149538 *

Also Published As

Publication number Publication date
WO2024252368A2 (en) 2024-12-12

Similar Documents

Publication Publication Date Title
WO2024252368A3 (en) Methods and compositions for treating ulcerative colitis
Cirino et al. Longitudinal predictors of the overlap between reading and math skills
MA54261A (en) PCSK9 INHIBITORS AND METHODS OF USE THEREOF
EP3911640A4 (en) PCSK9 INHIBITORS AND METHODS OF USE THEREOF
DE60219801D1 (en) COMPLEMENT INHIBITORS THAT CONNECT TO C5 AND C5a WITHOUT THE FORMATION OF C5b
MA52753A (en) ANTI-SIRPA ANTIBODIES AND THEIR METHODS OF USE
EP3977651A4 (en) SYSTEMS AND METHODS FOR WATERMARKING TIME, PLACE AND IDENTITY OF EVENTS
BR112018014146A2 (en) rapid antimicrobial susceptibility testing methods
MA55025A (en) ANTI-TREM2 ANTIBODIES AND METHODS OF USE THEREOF
EP3509637A4 (en) METHODS OF USING A BISPECIFIC ANTIBODY THAT RECOGNIZES COAGULATION FACTOR IX AND / OR ACTIVATED COAGULATION FACTOR IX AND COAGULATION FACTOR X AND / OR ACTIVATED COAGULATION FACTOR X
EP3962479A4 (en) KCNT1 INHIBITORS AND METHODS OF USE
EP3962481A4 (en) KCNT1 INHIBITORS AND METHODS OF USE
MA54955A (en) ANTI-CLAUDINE 6 ANTIBODIES AND THEIR USES
MA51837A (en) ARGINASE INHIBITORS AND METHODS OF USE THEREOF
EP3953385A4 (en) CD19 ANTIBODIES AND METHODS OF USE THEREOF
EP4284365A4 (en) CDK2 INHIBITORS AND METHODS OF USE THEREOF
MA51207A (en) ANTI-TRKB MONOCLONAL ANTIBODIES AND METHODS OF USE
EP3938785A4 (en) USE OF MAGNETIC NANOPARTICLES FOR THE DETECTION AND QUANTIFICATION OF ONE OR MORE ANALYTES
EP4144859A4 (en) REAGENT AND KIT FOR THE DETECTION OF TUMORS
Caillon et al. Overcoming the interference of daratumumab with immunofixation electrophoresis (IFE) using an industry-developed dira test: hydrashift 2/4 daratumumab
EA202190056A1 (en) ANTIBODIES AGAINST FACTOR XII / XIIa AND THEIR APPLICATION
Killackey Resignation not accepted: employment, education and training in early intervention, past, present and future.
EP3997121A4 (en) ANTIBODIES SPECIFICALLY RECOGNIZING PSEUDOMONAS PCRV AND THEIR USES
DE60024809D1 (en) USE OF ANTI-HBP ANTIBODY INHIBITING THE RELEASE OF BRADYKININE
EP3956448A4 (en) AIM2 INHIBITORS AND THEIR USES

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24736079

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE